One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get ...

One morning, Mallory Wilkerson woke up to a strange tingling in her hands and feet — like they had fallen asleep overnight.

A 22-year-old youth recovered from Guillain-Barré Syndrome (GBS) after an 96-day stay in Nanded's Dr Shankarrao Chavan Gove.

The election came after he collapsed at home in December with Guillain-Barré syndrome, a rare condition that affects the nervous system, leaving him unable to fully campaign. Mr Pardy said, while ...

He insisted that he was still able to go to work, but his partner Alix, 31, realised he wasn’t well and took him to A&E, where he was diagnosed with Guillain-Barre Syndrome (GBS) – a rare ...

Date/Time: Monday, May 19, from 3:55 pm to 4:10 pm British Summer Time (BST) Poster Presentations “Linking Early Complement Inhibition to Long-Term Outcomes in GBS: Objective Measures Support ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005 ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. | As it advances a ...

First Placebo-Controlled Phase 3 Trial for GBS Presented in AAN Oral Presentation. In the Phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and ...

BRISBANE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease ...

In the Phase 3 pivotal trial of 241 patients, tanruprubart met the primary endpoint with consistent outcomes and rapid, more complete functional recovery versus placebo across multiple time points ...